Skip to content

Pemvidutide

An investigational once-weekly GLP-1 and glucagon receptor dual agonist designed to spare lean mass during weight loss. It is not yet approved.

Half-life
5.0 d
Out of system
~4 weeks
Route
Subcutaneous
Level
Advanced

Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~4 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.

What Pemvidutide is used for

  • Dual GLP-1 and glucagon action drives weight loss with high energy expenditure
  • Designed to preserve lean muscle mass during fat loss
  • Once-weekly subcutaneous dosing

How it's typically used

Trial range: titrated toward roughly 1.2 mg subcutaneously once weekly in obesity studies, as reported in the literature.

What to watch for

  • GI side effects and possible heart-rate increases can occur
  • Glucagon agonism requires metabolic monitoring
  • Investigational; not approved for any use

About GLP-1 & weight loss

What they are
Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
How they're run
One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
What to watch
Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.

Full guide

Pemvidutide: A Tracking Guide for a GLP-1 and Glucagon Agonist

A neutral, harm-reduction guide to pemvidutide, an investigational GLP-1/glucagon agonist noted for lean-mass sparing and MASH data.

Other glp-1 & weight loss

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.